A Potential Role for the CDH13/CDH15 Gene in Repeat Revascularization After First Percutaneous Coronary Intervention

Abstract

Aim: Major drawbacks of percutaneous coronary intervention are the high occurrence of repeat revascularization due to restenosis and disease progression. The aim of this study was to find genetic indicators to predict the risk of repeat revascularization. Materials & methods: From April 2015 to June 2016, 143 patients with percutaneous coronary intervention with genetic test results were enrolled. SNPs were measured by OmniZhongHua-8, and the SNPs in pathways genes related to known stenosis-related processes from the KEGG, BioCarta and Gene Cards databases were selected for analysis. Results: Cell–extracellular matrix interactions were the pathways with the most significant SNP (CDH15 rs72819363) association with repeat revascularization. Compared with CDH13 rs11859453G carriers, the adjusted odds ratio for A carriers was 0.25 and 0.33 at 18 and 30 months. Conclusion: We demonstrated a potential role of the cell–extracellular matrix interactions pathway and the possible biomarker CDH13/CDH15 in the development of coronary repeat revascularization.

Keywords::

• genetic polymorphism
• percutaneous coronary intervention
• repeat revascularization
• restenosis

Author contributions

Q Xiang and Y Cui were responsible for study conception and design. Z Liu, S Chen and S Zhou were responsible for acquisition of data. J Mao, X Zhao, Q Xie, Z Wang and G Mu were responsible for data analysis. Q Xiang and Z Liu were responsible for drafting and revision of the manuscript. Y Lu was responsible for the revision of the manuscript. J Jiang and Y Gong were responsible for enrolling the patients.

Financial & competing interests disclosure

This study was supported by grants from the National Natural Science Foundation of China (No. 81673509 and No. 81573504), National Key Technologies R&D Program (No. 2016YFC0904900), Beijing Natural Science Foundation (No. 7171012) and National Science and Technology Major Projects for “Major New Drugs Innovation and Development” (No. 2017ZX09304028 and No. 2017ZX09101001). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This study was supported by grants from the National Natural Science Foundation of China (No. 81673509 and No. 81573504), National Key Technologies R&D Program (No. 2016YFC0904900), Beijing Natural Science Foundation (No. 7171012) and National Science and Technology Major Projects for “Major New Drugs Innovation and Development” (No. 2017ZX09304028 and No. 2017ZX09101001). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.